Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.85 |
| ▸ | FBP1 | P09467 | 2/20 | 0.85 |
| ▸ | KDR | P35968 | 2/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.85 |
| ▸ | AURKA | O14965 | 1/20 | 0.85 |
| ▸ | INSR | P06213 | 1/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.85 |
| ▸ | FLT4 | P35916 | 1/20 | 0.85 |
| ▸ | CLK1 | P49759 | 1/20 | 0.85 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.85 |
| ▸ | TEK | Q02763 | 1/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.85 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17520369 | 0.95 | EGFR (0.85) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL2099106 | 0.92 | EGFR (1.00) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL30505605 | 0.92 | EGFR (1.00) | EGFRFBP1KDRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL27887194 | 0.91 | EGFR (0.98) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL18655505 | 0.89 | FBP1 (0.85) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL7814811 | 0.88 | EGFR (0.89) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL7807648 | 0.88 | EGFR (0.89) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL12788058 | 0.88 | EGFR (0.72) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL8383 | 0.88 | EGFR (0.83) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL8208160 | 0.88 | EGFR (0.83) | EGFRFBP1KDRERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-9546179-B2 | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof | Qian, Wei (CN) | 2017-01-17 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140206664-A1 | Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof | QIAN WEI (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2011098607-A1 | SALTS AND HYDRATES OF 4-[(3-CHLOR-4-FLUORO-PHENYL)AMINO]-6-(CIS-4-{N-[(MORPH-1-OLINO-4-YL)CARBONYL]-N-METHYL-AMINO}-CYCLOHEXANE-1-YLOXY)-7-METHOXY-QUINAZOLINE, THEIR USE AS DRUGS AND THEIR PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885FBP1 4095/4885KDR 949/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | EGFR 2358/4885FBP1 1877/4885KDR 2667/4885 |
| US-20140206664-A1 | Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885FBP1 3894/4885KDR 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.